Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation.
Hosseini A. et al, (2025), Nature
INCA033989: the first shot on goal for MPNs?
Benlabiod C. and Psaila B., (2024), Blood, 144, 2278 - 2279
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
O'Sullivan J. et al, (2024), British Journal of Haematology
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Li R. et al, (2024), Sci Transl Med, 16
Generating human bone marrow organoids for disease modeling and drug discovery.
Olijnik A-A. et al, (2024), Nat Protoc
Modelling niche influences on blood cancer development
Psaila B., (2024), HEMATOLOGIE, 30, 121 - 122
Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806
RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
Brierley CK. et al, (2024), BLOOD, 144, 3146 - 3147
Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A.
Brierley CK. et al, (2023), bioRxiv
The management of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2023), Br J Haematol
Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.
Rampotas A. et al, (2023), Blood
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2023), Br J Haematol
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A. et al, (2023), Nat Genet, 55, 1531 - 1541